Bionexus Gene Lab Corp (BGLC)

$3.70 -0.59 (-13.75%)
Market Cap 7.71M
Revenue (ttm) 9.51M
Net Income (ttm) -1.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16.82%
Debt to Equity Ratio 0.00
Volume 154,800
Avg Vol 822,703
Day's Range N/A - N/A
Shares Out 1.80M
Stochastic %K 43%
Beta 5.20
Analysts Strong Buy
Price Target N/A

Latest News on BGLC

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

Apr 30, 2025, 11:25 AM EDT - 4 weeks ago

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

Apr 15, 2025, 11:00 AM EDT - 7 weeks ago

BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

Mar 7, 2025, 11:00 AM EST - 3 months ago

BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper

Mar 5, 2025, 11:00 AM EST - 3 months ago

BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

Sep 25, 2024, 11:31 AM EDT - 8 months ago

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

Sep 13, 2024, 12:05 PM EDT - 9 months ago

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

Sep 12, 2024, 1:23 PM EDT - 9 months ago

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

Sep 11, 2024, 11:05 AM EDT - 9 months ago

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

Aug 27, 2024, 11:35 AM EDT - 10 months ago

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

Aug 26, 2024, 12:15 PM EDT - 10 months ago

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

Apr 18, 2024, 2:52 PM EDT - 1 year ago

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market

Jul 24, 2023, 11:30 AM EDT - 2 years ago

BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market

BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Jul 20, 2023, 1:29 PM EDT - 2 years ago

BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market